Not checked for notices yet.

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity

Haijun Tang, Haijun Tang, Long Gao and 15 more

Frontiers in Cellular and Infection Microbiology · 2021

doi:10.3389/fcimb.2021.720357

References 49

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) · 2016
No notice
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
Why are RNA virus mutation rates so damn high? · 2018
No notice
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
No notice
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 · 2020
No notice
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
Site-specific glycan analysis of the SARS-CoV-2 spike · 2020
No notice
24.
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies · 2020
No notice
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy · 2020
No notice
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial · 2020
No notice
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants · 2020
No notice
34.
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo · 2020
No notice
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 · 2021
No notice
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
41.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
42.
SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape · 2021
No notice
43.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
44.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
45.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
46.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
47.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
48.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
49.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 1

Mutations and Evolution of the SARS-CoV-2 Spike Protein · 2022
Corrected

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.